News & Events
Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
Crinetics today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at...
READ MORECrinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Crinetics today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise...
READ MORECrinetics Pharmaceuticals Announces Pricing of Initial Public Offering
Crinetics today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering...
READ MORECrinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
Crinetics Pharmaceuticals, Inc., today announced that it has been awarded up to approximately $3.2 million in Small Business Innovation Research...
READ MORECrinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare...
READ MORETop News: Crinetics raises $63.5 million in new funds and adds to BOD
Crinetics has completed a $63.5 million Series B financing to continue development of its lead product for acromegaly and other...
READ MORECrinetics Pharmaceuticals Completes $63.5 Million Series B Financing
The investment was led by Perceptive Advisors and includes new investors RA Capital and OrbiMed. Existing investors 5AM Ventures, Versant...
READ MORECrinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
SAN DIEGO – March 12, 2018 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and...
READ MORECrinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers,...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
